These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21658092)

  • 1. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.
    Montastruc JL; Sommet A; Bagheri H; Lapeyre-Mestre M
    Br J Clin Pharmacol; 2011 Dec; 72(6):905-8. PubMed ID: 21658092
    [No Abstract]   [Full Text] [Related]  

  • 2. When to publish measures of disproportionality derived from spontaneous reporting databases?
    de Boer A
    Br J Clin Pharmacol; 2011 Dec; 72(6):909-11. PubMed ID: 21848575
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database.
    Renoud L; Khouri C; Revol B; Lepelley M; Perez J; Roustit M; Cracowski JL
    JAMA Intern Med; 2021 Sep; 181(9):1243-1245. PubMed ID: 33904857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.
    Chavant F; Favrelière S; Lafay-Chebassier C; Plazanet C; Pérault-Pochat MC
    Br J Clin Pharmacol; 2011 Dec; 72(6):898-904. PubMed ID: 21557759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study.
    Mouffak A; Lepelley M; Revol B; Bernardeau C; Salvo F; Pariente A; Roustit M; Cracowski JL; Khouri C
    J Clin Epidemiol; 2021 Oct; 138():73-79. PubMed ID: 34186195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.
    Khouri C; Petit C; Tod M; Lepelley M; Revol B; Roustit M; Cracowski JL
    J Clin Epidemiol; 2021 Jun; 134():14-21. PubMed ID: 33508405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to onset in statistical signal detection revisited: A follow-up study in long-term onset adverse drug reactions.
    Scholl JHG; van Hunsel FPAM; Hak E; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1283-1289. PubMed ID: 31189217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
    Sato K; Mano T; Iwata A; Toda T
    J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
    Scholl JH; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk for aseptic meningitis after amoxicillin or amoxicillin-clavulanic acid in males: A signal revealed by subset disproportionality analysis within a global database of suspected adverse drug reactions.
    Chandler RE
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):389-395. PubMed ID: 30556617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study.
    de Vries ST; Denig P; Ekhart C; Burgers JS; Kleefstra N; Mol PGM; van Puijenbroek EP
    Br J Clin Pharmacol; 2019 Jul; 85(7):1507-1515. PubMed ID: 30941789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use.
    Caster O; Sandberg L; Bergvall T; Watson S; Norén GN
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):1006-1010. PubMed ID: 28653790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase.
    Roselli A; Khouri C; Roustit M; Blaise S; Cracowski JL
    Dermatol Surg; 2019 Dec; 45(12):1517-1528. PubMed ID: 30829775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China.
    Hou Y; Ye X; Wu G; Cheng G; Du X; He J
    Expert Opin Drug Saf; 2014 Jul; 13(7):853-7. PubMed ID: 24918197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
    Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
    J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.